Celldex Therapeutics Inc.

Celldex Therapeutics Inc.

Celldex Therapeutics Inc.

Overview
Date Founded

1983

Headquarters

Perryville III Building,53 Frontage Road,Suite 220,Hampton, NJ 08827

Type of Company

Public

Employees (Worldwide)

197

Industries

Pharmaceuticals
Pension Funds & Sovereign Wealth
Hospitals & Patient Services
Biotechnology

Company Description

Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega. Celldex Therapeutics was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Contact Data
Trying to get in touch with decision makers at Celldex Therapeutics Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder, President, Chief Executive Officer & Director

Founder

Senior Vice President, Treasurer & Chief Financial Officer

Senior Vice President & Chief Commercial Officer

Senior Vice President & Chief Business Officer

Senior Vice President, Chief Product Development Officer

Senior Vice President Corporate Affairs & Administration

Senior Vice President, Regulatory Affairs

Senior Director

Board of Directors

Founding Partner at Healthcare Ventures Associates, Inc.

Former Managing Partner at Dechert LLP

Former Audit Partner at Ernst & Young LLP

Founder at New Haven Pharmaceuticals, Inc.

President, Chief Executive Officer & Director at Harpoon Therapeutics, Inc.

Paths to Celldex Therapeutics Inc.
Potential Connections via
Relationship Science
You
Celldex Therapeutics Inc.
Owners & Shareholders
Details Hidden

Meditor is an active, long-term, generalist, fundamentals-based manager which employs a bottom-up approach to invest in European equities. They have a specialization in healthcare and consumer goods.The firm invests across market caps and believes that different companies need to be measured by different metrics. Their investment managers conduct an extensive program of company visits complemented by external research from a network of consultants.Meditor's investment style is pro-active and event-driven, involved in turnaround investments, with a preference for the technology sector. The firm has previously invested in troubled companies, implemented management shake-ups, subsequently selling business branches to unlock value.

Details Hidden

KLP Enterprises LLC is an American private company located in New Haven, CT. The firm provides investment advice. Andrew D. Wingate is currently the CEO of the company.

Details Hidden

Meditor is an active, long-term, generalist, fundamentals-based manager which employs a bottom-up approach to invest in European equities. They have a specialization in healthcare and consumer goods.The firm invests across market caps and believes that different companies need to be measured by different metrics. Their investment managers conduct an extensive program of company visits complemented by external research from a network of consultants.Meditor's investment style is pro-active and event-driven, involved in turnaround investments, with a preference for the technology sector. The firm has previously invested in troubled companies, implemented management shake-ups, subsequently selling business branches to unlock value.

Recent Transactions
Details Hidden

Celldex Therapeutics Inc. raised money in a private placement transaction

Details Hidden

Celldex Therapeutics Inc. purchases Kolltan Pharmaceuticals, Inc. from HBM Partners AG, Osage Partners LLC, Elm Street Venture Advisors, Inc., Auven Therapeutics Management LLLP, Tichenor Ventures LLC, Sectoral Asset Management Inc (Private Equity)

Details Hidden

Celldex Therapeutics Inc. issued Common Stock

Transaction Advisors
Underwriter

Advised onCelldex Therapeutics Inc. issued Common Stock

Underwriter

Advised onCelldex Therapeutics Inc. issued Common Stock

Auditor

Advised onCelldex Therapeutics Inc. issued Common Stock

Legal Advisor

Advised onCelldex Therapeutics Inc. issued Common Stock

Managing Director

Advised onCelldex Therapeutics Inc. issued Common Stock

Underwriter

Advised onCelldex Therapeutics Inc. issued Common Stock

Advisors & Consultants
Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Publicist

Founder at 1AB Media

Publicist

Founder at 1AB Media

Clients

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

The Rockefeller University is a world-renowned center for research and graduate education in the biomedical sciences, chemistry, bioinformatics and physics. The university’s 72 laboratories conduct both clinical and basic research and study a diverse range of biological and biomedical problems with the mission of improving the understanding of life for the benefit of humanity. Founded in 1901 by John D. Rockefeller, the Rockefeller Institute for Medical Research was the country’s first institution devoted exclusively to biomedical research. The Rockefeller University Hospital was founded in 1910 as the first hospital devoted exclusively to clinical research. In the 1950s, the institute expanded its mission to include graduate education and began training new generations of scientists to become research leaders around the world. In 1965, it was renamed The Rockefeller University. The university is supported by a combination of government and private grants and contracts, private philanthropy and income from the endowment. Since its founding, The Rockefeller University has embraced an open structure to encourage collaboration between disciplines and empower faculty members to take on high-risk, high-reward projects. No formal departments exist, bureaucracy is kept to a minimum and scientists are given resources, support and unparalleled freedom to follow the science wherever it leads. This unique approach to science has led to some of the world’s most revolutionary contributions to biology and medicine. Throughout Rockefeller’s history, 24 of its scientists have won Nobel Prizes, 21 have won Lasker Awards and 20 have garnered the National Medal of Science, the highest science award given by the United States. For more than 100 years, The Rockefeller Hospital has served as an essential link between laboratory investigation and bedside observation, as patients are participants in clinical studies building on basic research findings from Rockefeller laboratories. This continuous spectrum of research allows for in-depth study of the basis of disease detection, prevention and observation. The David Rockefeller Graduate Program is based on the concept of learning science by doing science, and is custom tailored to its individual students and attracts a diverse group of exceptional scientists from around the world. The university also offers one of the nation’s top M.D.-Ph.D. programs with neighboring Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College. In addition to the graduate program, there are other learning/training opportunities available, including postdoctoral research, fellowships for the Center for Studies in Physics and Biology and the Clinical Scholars Program, a master's degree for recent M.D. or M.D.-Ph.D. recipients to begin careers in patient-oriented research

International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm also supports a comprehensive approach to HIV and AIDS that balances the expansion and strengthening of existing HIV prevention and treatment programs with targeted investments in new AIDS prevention technologies. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY.

Key Stats and Financials As of 2017
Market Capitalization
$65.1M
Total Enterprise Value
$226M
Earnings Per Share
$-10.8
Revenue
$12.7M
EBITDAMargin
-816.27%
Net Profit
$-93M
EBITDA
$-104M
Total Equity
$236M
Enterprise Value Sales
17.73x
TEVNet Income
-2.43x
Debt TEV
0x
Total Debt
$0
Three Year Compounded Annual Growth Rate Of Revenue
52.6%
Five Year Compounded Annual Growth Rate Of Revenue
2.61%
Non-Profit Donations & Grants
$5,000 - $10K
2008
Suppliers
Ambio Holdings, Inc. Holding Companies | North Augusta, SC

Ambio Holdings, Inc. operates as a pharmaceutical company which focuses on complex peptides. It develops processes for manufacturing peptides at small to large scale as active pharmaceutical ingredients used in New Chemical Entities and generic peptides by clients worldwide. The company was founded by Chris J. Bai in 2014 and is headquartered in North Augusta, SC.

Amgen, Inc. Biotechnology | Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Bristol-Myers Squibb Company Medical Support Services | New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Pfizer, Inc. Pharmaceuticals - WASHINGTON, DC

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Novartis AG Pharmaceuticals - Basel, BS

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Celldex Therapeutics Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Celldex Therapeutics Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Celldex Therapeutics Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/celldex-therapeutics-inc-1000727
  • https://relationshipscience.com/organization/celldex-therapeutics-inc-1000727